Huntsworth (HNT) PT Raised to GBX 125

Share on StockTwits

Huntsworth (LON:HNT) had its price target raised by Berenberg Bank from GBX 120 ($1.57) to GBX 125 ($1.63) in a report issued on Thursday morning, ThisIsMoney.Co.Uk reports. The firm currently has a buy rating on the stock.

HNT has been the subject of several other reports. Peel Hunt restated a buy rating on shares of Huntsworth in a report on Tuesday, March 5th. Numis Securities restated a buy rating and issued a GBX 165 ($2.16) price target on shares of Huntsworth in a report on Thursday, May 9th.

Shares of Huntsworth stock opened at GBX 101 ($1.32) on Thursday. Huntsworth has a 1 year low of GBX 76.60 ($1.00) and a 1 year high of GBX 140 ($1.83). The stock has a market capitalization of $352.45 million and a price-to-earnings ratio of 16.56. The company has a quick ratio of 1.29, a current ratio of 1.46 and a debt-to-equity ratio of 50.92.

The firm also recently declared a dividend, which will be paid on Thursday, July 4th. Shareholders of record on Thursday, May 23rd will be issued a GBX 1.60 ($0.02) dividend. This is an increase from Huntsworth’s previous dividend of $0.70. This represents a dividend yield of 1.78%. The ex-dividend date of this dividend is Thursday, May 23rd. Huntsworth’s dividend payout ratio is 0.33%.

Huntsworth Company Profile

Huntsworth plc, together with its subsidiaries, operates as a healthcare and communications company in the United Kingdom and rest of Europe, the United States, and internationally. The company operates through four divisions: Medical, Marketing, Immersive, and Communications. The Medical division provides scientific strategy and communications, publications planning and delivery, specialized medical writing, medical education, and payer and value communications services, as well as support services for internal medical teams.

Further Reading: Are sell-side analysts objective?

Receive News & Ratings for Huntsworth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Huntsworth and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Barry Zwarenstein Sells 7,663 Shares of Five9 Inc  Stock
Barry Zwarenstein Sells 7,663 Shares of Five9 Inc Stock
Venture Fund Vii L.P. Arch Sells 63,000 Shares of Syros Pharmaceuticals Inc  Stock
Venture Fund Vii L.P. Arch Sells 63,000 Shares of Syros Pharmaceuticals Inc Stock
Insider Selling: Neogen Co.  Director Sells 5,000 Shares of Stock
Insider Selling: Neogen Co. Director Sells 5,000 Shares of Stock
Neogen Co.  Director Sells $314,650.00 in Stock
Neogen Co. Director Sells $314,650.00 in Stock
Insider Selling: Airgain Inc  CEO Sells 22,464 Shares of Stock
Insider Selling: Airgain Inc CEO Sells 22,464 Shares of Stock
Insider Selling: Bottomline Technologies  Insider Sells 9,925 Shares of Stock
Insider Selling: Bottomline Technologies Insider Sells 9,925 Shares of Stock


© 2006-2019 Ticker Report